Renal functional and surgical outcomes after robot-assisted partial nephrectomy for hilar vs non-hilar tumors: Trifecta and pentafecta evaluation

Table 1 Patient characteristics, n (%)/median (interquartile range)

Characteristics		Entire cohort				Propensity matched cohort
		Entire cohort, n = 324	Hilar tumor, n = 60	Non-hilar tumor, n = 264	P value	Hilar tumor, n = 60	Non-hilar tumor, n = 60	P value	SMD
Age (years)		66 (28-92)	66 (39-85)	66 (28-92)	0.909	66 (39-85)	66 (37-92)	0.956	0.011
Sex (%)	Male	230 (71.0)	44 (73.3)	186 (70.5)	0.753	44 (73.3)	41 (68.3)	0.688	0.110
BMI (kg/m2)		24.0 (14-45.2)	23.9 (17.3-35.3)	24 (14-45.2)	0.949	23.9 (17.3-35.3)	23.6 (15.7-32.6)	0.103	0.322
ECOG-PS (%)	0	279 (86.1)	54 (90)	225 (85.2)	0.616	54 (90)	54 (90.0)	1	< 0.001
	1	44 (13.6)	6 (10)	38 (14.4)		6 (10)	6 (10.0)
	2	1 (0.3)	0	1 (0.4)		0	0
Comorbidity (%)	Diabetes mellitus	85 (26.2)	17 (28.3)	68 (25.8)	0.745	17 (28.3)	43 (71.7)	1	< 0.001
	Hypertension	147 (45.4)	29 (48.3)	118 (44.7)	0.667	29 (48.3)	17 (28.3)
Laterality (%)	Right	177 (54.6)	34 (56.7)	143 (54.2)	0.775	34 (56.7)	31 (51.7)	0.714	0.100
	Left	147 (45.4)	26 (43.3)	121 (45.8)		26 (43.3)	29 (48.3)
Preoperative estimated glomerular filtration rate (mL/minute/1.73 m2)		70.0 (17.9-115.2)	71 (22.7-96.3)	69.6 (17.9-115.2)	0.920	71 (22.7-96.3)	68.6 (25.4-100.1)	0.902	0.017
Preoperative CKD staging (%)1	I	26 (8.0)	2 (3.3)	24 (9.1)	0.516	2 (3.3)	6 (10.0)	0.402	0.324
	II	197 (60.8)	39 (65.0)	158 (59.8)		39 (65.0)	33 (55.0)
	III	91 (28.1)	17 (28.3)	74 (28.0)		17 (28.3)	20 (33.3)
	IV	10 (3.1)	2 (3.3)	8 (3.0)		2 (3.3)	1 (1.7)
Tumor size (mm)		3.1 (11-69)	3.3 (10-69)	3.0 (11-68)	0.134	3.3 (10-69)	3.4 (1.2-5.8)	0.994	0.007
Medical device (%)	DaVinci	319 (98.5)	59 (98.3)	260 (98.5)	1	59 (98.3)	59 (98.3)	1	< 0.001
	Hinotori	5 (1.5)	1 (1.7)	4 (1.5)		1 (1.7)	1 (1.7)
Approach (%)	Intra	199 (61.4)	33 (55.0)	166 (62.9)	0.304	33 (55.0)	34 (56.7)	1	0.034
Surgeon’s experience (cases > 20) (%)	≥ 20	216 (66.7)	45 (75.0)	171 (64.8)	0.172	45 (75.0)	42 (70.0)	0.683	0.112
R score (%)1	1	236 (72.8)	44 (73.3)	192 (72.7)	1	44 (73.3)	39 (65.0)	0.429	0.181
	2	88 (27.2)	16 (26.7)	72 (27.3)		16 (26.7)	21 (35)
E score (%)	1	115 (35.5)	15 (25.0)	100 (37.9)	0.105	15 (25.0)	16 (26.7)	0.893	0.102
	2	142 (43.8)	28 (46.7)	114 (43.2)		28 (46.7)	25 (41.5)
	3	67 (20.7)	17 (28.3)	50 (18.9)		17 (28.3)	19 (31.7)
N score (%)	1	36 (11.7)	2 (3.3)	34 (12.9)	0.047b	2 (3.3)	2 (3.3)	0.915	0.104
	2	55 (17.0)	8 (13.3)	47 (17.8)		8 (13.3)	6 (10.0)
	3	233 (71.9)	50 (83.3)	183 (69.3)		50 (83.3)	52 (86.7)
A score (%)1	A	75	29 (48.3)	109 (41.3)	0.569	29 (48.3)	29 (48.3)	0.720	0.149
	P	111	20 (33.3)	92 (34.8)		20 (33.3)	20 (33.3)
	X	148	11 (18.3)	63 (23.9)		11 (18.3)	11 (18.3)
L score (%)	1	102	0	102 (38.6)	< 0.001c	0	0	1	0.036
	2	93	18 (30.0)	75 (28.4)		18 (30.0)	19 (31.7)
	3	129	42 (70.0)	87 (33.0)		42 (70.0)	41 (68.3)
Renal score (%)1	4	9 (2.8)	9 (3.4)	0	< 0.001c	0	0	0.574	0.432
	5	27 (8.3)	2 (3.3)	25 (9.5)		2 (3.3)	1 (1.7)
	6	37 (11.4)	0 (0)	37 (14.0)		0 (0)	3 (5.0)
	7	56 (17.3)	4 (6.7)	52 (19.7)		4 (6.7)	2 (3.3)
	8	64 (19.8)	13 (21.7)	51 (19.3)		13 (21.7)	12 (20.0)
	9	79 (24.4)	24 (40.0)	55 (20.8)		24 (40.0)	21 (35.0)
	10	47 (14.5)	16 (26.7)	31 (11.7)		16 (26.7)	18 (30.0)
	11	5 (1.5)	1 (1.7)	5 (1.5)		1 (1.7)	3 (5.0)

^bP < 0.01.

^cP < 0.001.

¹Propensity unmatched.

SMD: Standardized mean difference; BMI: Body mass index; ECOG-PS: Eastern Cooperative Oncology Group Performance Status, CKD: Chronic kidney disease.